Lineage Cell Therapeutics, Inc.
LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyteā¦ read more
Healthcare
Biotechnology
33 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.68
Price-4.00%
-$0.07
1Y
Price
Market Cap
$386.457m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-803.4%
EBITDA Margin-809.0%
Net Profit Margin-98.6%
Free Cash Flow MarginRevenue
$10.816m
+13.9%
1y CAGR-6.4%
3y CAGR+64.6%
5y CAGREarnings
-$67.657m
-263.6%
1y CAGR-77.3%
3y CAGR-48.3%
5y CAGREPS
-$0.29
-222.2%
1y CAGR-59.1%
3y CAGR-33.7%
5y CAGRBook Value
$20.796m
$89.639m
Assets$68.843m
Liabilities$2.621m
DebtDebt to Assets
2.9%
-0.1x
Debt to EBITDAFree Cash Flow
-$20.875m
+11.8%
1y CAGR-1531.8%
3y CAGR-1123.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company